EVISTA? is a targeted therapy developed specifically to protect bone health in postmenopausal women at risk of osteoporosis and related fractures. It helps prevent bone loss and increase bone mineral density, thereby reducing the risk of spinal fractures associated with postmenopausal osteoporosis. A key advantage of EVISTA? is its tissue-selective action, which delivers estrogen-like benefits on bone while not stimulating breast or uterine tissue, making it a safer long-term option for women who require bone protection without increased risk to hormone-sensitive tissues.